Based on the observation that Akt is activated following AICAR treatment in ALL cells, we hypothesized that inhibition of the PI3K/Akt pathway through inactivation of mTOR using rapamycin should enhance the cytotoxic activity of AICAR. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.